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Reduced-intensity and non-myeloablative allogeneic stem cell
transplantation from alternative HLA-mismatched donors for
Hodgkin lymphoma: a study by the French Society of Bone
Marrow Transplantation and Cellular Therapy
J Gauthier1,2, L Castagna3, F Garnier4, T Guillaume5, G Socié6, S Maury7, N Maillard8, R Tabrizi9, T Marchand10, J Malfuson11, A Gac12,
E Gyan13, M Mercier14, Y Béguin15, J Delage16, P Turlure17, A Marçais18, S Nguyen19, R Dulery20, J Bay21, A Huynh22, E Daguindau23,
J Cornillon24, C Régny25, M Michallet26, R Peffault de Latour6, I Yakoub-Agha1,2 and D Blaise27
Allogeneic stem cell transplantation (allo-SCT) following a non-myeloablative (NMA) or reduced-intensity conditioning (RIC) is
considered a valid approach to treat patients with refractory/relapsed Hodgkin lymphoma (HL). When an HLA-matched donor is
lacking a graft from a familial haploidentical (HAPLO) donor, a mismatched unrelated donor (MMUD) or cord blood (CB) might be
considered. In this retrospective study, we compared the outcome of patients with HL undergoing a RIC or NMA allo-SCT from
HAPLO, MMUD or CB. Ninety-eight patients were included. Median follow-up was 31 months for the whole cohort. All patients in
the HAPLO group (N= 34) received a T-cell replete allo-SCT after a NMA (FLU-CY-TBI, N= 31, 91%) or a RIC (N= 3, 9%) followed by
post-transplant cyclophosphamide. After adjustment for signiﬁcant covariates, MMUD and CB were associated with signiﬁcantly
lower GvHD-free relapse-free survival (GRFS; hazard ratio (HR) = 2.02, P= 0.03 and HR= 2.43, P= 0.009, respectively) compared with
HAPLO donors. In conclusion, higher GRFS was observed in Hodgkin lymphoma patients receiving a RIC or NMA allo-SCT with post-
transplant cyclophosphamide from HAPLO donors. Our ﬁndings suggest they should be favoured over MMUD and CB in this
setting.
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INTRODUCTION
Although Hodgkin’s lymphoma (HL) can be cured in a majority
of cases with ﬁrst-line chemotherapy, prognosis remains
poor when patients relapse or progress after intensive chemo-
therapy followed by autologous stem cell transplantation.
On the basis of some retrospective data1 such patients
may beneﬁt from an allogeneic stem cell transplantation
(allo-SCT) with reduced-intensity conditioning (RIC) from an
HLA-matched donor.
When no HLA-compatible sibling can be identiﬁed—in about
75% of cases—an HLA-matched unrelated donor is usually
available in 50 to 60% of patients. There are today limited data
regarding the use of alternative HLA-mismatched donors in
HL patients undergoing allo-SCT.
After cord blood (CB) allo-SCT for HL, high relapse rates
(30–40% at 1 year) have been reported2–4 in line with a
retrospective study from our group that observed poorer outcome
compared with HLA-matched related and unrelated donors.5
Although some other studies6–9 included patients transplanted
from mismatched unrelated donors (MMUD), most numbers
were limited, which precluded further analysis. Those studies
showed not only high relapse rates after RIC allo-SCT from
a MMUD but also high treatment-related mortality (TRM).
More promising results have been reported by the Seattle
group8 and more recently by Raiola et al.10 with T-cell replete,
non-myeloablative (NMA) haploidentical (HAPLO) allo-SCT with
post-transplant cyclophosphamide (PT CY). Using this approach,
low TRM, low incidence of chronic GvHD (cGvHD), as well
as acceptable relapse rates were reported. Some preliminary
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data might even favour HAPLO over unrelated HLA-matched
donors in advanced non-Hodgkin lymphomas.11
Because of the lack of comparative data regarding allo-SCT
from alternative HLA-mismatched donors for HL patients, we
designed this retrospective, multicentre study to evaluate the
outcome of HL patients receiving an allo-SCT prepared with RIC or
NMA conditioning from one of the three types of alternative
donors: HAPLO, mismatched unrelated donors (MMUD) and
CB grafts.
MATERIALS AND METHODS
This study was approved by the French Society of Bone Marrow
Transplantation and Cell Therapies (SFGM-TC) board and conducted
in agreement with the declaration of Helsinki. Informed consent was
obtained from all subjects.
Patient selection
After detailed review of the database, we found 98 consecutive patients with
HL who underwent a RIC or NMA allo-SCT from an alternative HLA-
mismatched donor at 24 French and Belgian centers between January 2009
and December 2014. Histological diagnosis was based on local review.
Disease status at transplant, progression and relapse after allo-SCT were
reviewed and assessed by PET-scan and/or CT scan, according to the criteria
published by Cheson et al.12,13 Although detailed Deauville classiﬁcation was
not systematically applied, PET negativity was deﬁned as a ﬂudeoxyglucose
uptake below or equal to the uptake measured in the liver.
Statistical analyses
Patient characteristics were displayed as numbers and percentages or as
medians and ranges. CMV risk was deﬁned as a CMV-seropositive in
recipient and/or in donor. Sex mismatch was deﬁned as the association of
a male recipient with a female donor. ABO mismatch was deﬁned as any
difference in blood type between donor and recipient. We evaluated
differences between groups using the χ2-test or the Fisher’s exact
test when appropriate. Overall survival (OS) was deﬁned as the interval
from allo-SCT to death, regardless of its cause. Progression and relapse
post-transplant were determined by applying Cheson’s criteria.12,13
Non-relapse mortality (NRM) was deﬁned as death resulting from the
transplant procedure without evidence of relapse or progression. Event-
Free Survival (EFS) was deﬁned as the probability of being alive without
evidence of relapse or treatment-related death. Because no data regarding
systemic therapy-requiring chronic GvHD were available in our database
we slightly altered the deﬁnition published by Holtan et al.14 regarding
GvHD-free relapse-free survival (GRFS). We deﬁned GRFS as the probability
of being alive without evidence of relapse, grade 3–4 acute GvHD or
chronic GvHD (cGvHD). All censored criteria were calculated from the time
of allo-SCT. The probabilities of OS, EFS and GRFS were estimated using the
Kaplan–Meier method. The Log rank test was used to determine the
prognostic value of patient characteristics on OS, EFS and GRFS.
The cumulative incidences of relapse (CIR), NRM and cGvHD were studied
using a competing risk methodology. For the event of relapse, NRM was
considered as the competing event and vice versa. For cGvHD, death was
the competing event. For aGvHD all patients who died before day
100 were excluded from the analysis. The cumulative incidence of each
event was estimated using the Kalbﬂeish and Prentice method.15 The
individual prognostic value on the CIR and NRM of each variable was
assessed by the Gray’s test. Backward selection of variables having a
signiﬁcance levelo0.15 in univariate analysis were introduced in a
multivariate Cox regression model for OS, EFS and GRFS. The proportional
hazard assumption for Cox regression models was tested using the cox.zph
function in the R software. No multivariate analysis was performed for
CIR and NRM as only one variable was at a P levelo0.15. All statistical
analyses were performed using the R software program.16
HLA typing and stem cell source
All the data regarding HLA-typing and stem cell source were cross-checked
with the data from the French Biomedical Agency (Agence Nationale de la
Biomédecine) and from the PRoMISE SFGM-TC database. Follow-up
data were updated by local investigators when needed. For unrelated
donors, mismatch was deﬁned as a difference in at least one HLA-A,
-B, -Cw, DR or DQ locus. In the MMUD group two mismatches
(8/10 HLA-compatible) were reported in three patients, while one
mismatch (9/10 HLA-compatible) was reported in 24 patients. Siblings
were considered haploidentical when they exhibited two to three
HLA mismatches on the unshared haplotype. For all CB grafts (N= 37),
HLA-A and HLA-B low-resolution typing was obtained, as well as
allelic, high-resolution typing for the DR locus. HLA matching for
CB patients was 3/6, 4/6, 5/6 and 6/6 in 2 (5%), 22 (60%), 11 (30%) and
2 (5%) patients, respectively. Eight patients (22%) received a single CB graft
while 29 (78%) received two units.
Conditioning and transplantation modalities
Conditioning intensity was deﬁned as previously described.17 All patients
received a RIC or a NMAC. A variety of conditioning regimen was used.
In the HAPLO group, 31 patients (88%) received the following
NMA conditioning regimen, previously described by the Baltimore
group:18 Cy 14.5 mg/kg on day − 6 and day − 5, ﬂudarabine 30 mg/m2
on day − 6 to day − 2 and low-dose TBI (2 Gy) on day − 1. The other
patients (N= 3) in the HAPLO group received a RIC. One patient received
thiotepa 5 mg/kg on day − 6, busulfan 3.2 mg/kg on day − 5 and day
− 4, ﬂudarabine 40 mg/m2 on day − 5 to day − 2. One patient was
conditioned with a total dose of ﬂudarabine of 180 mg/m2 and a total
dose of IV busulfan of 260 mg/m2. One patient was conditioned with
Cy 29 mg/kg associated with a total dose of ﬂudarabine of 150 mg/m2 and
a total dose of IV busulfan of 260 mg/m2. All patients in the HAPLO group
received PT CY. All but one patient (N= 33) in the HAPLO group received
the following GvHD prophylaxis: Cy 50 mg/kg on day +3 and day
+4, tacrolimus or CsA and mycophenolate mofetil started on day +5.
One patient received only one day of PT CY 50 mg/kg at day+3 and
also received ATG on day − 2 and day − 1 for a total dose of 5 mg/kg,
CsA and mycophenolate mofetil started on day +5. Donor type in
the HAPLO group was offspring (N=2), sibling (N= 17) or parent (N= 15).
T-cell replete grafts were used in all HAPLO patients (N= 34).
In patients who received an allo-SCT from a MMUD (N=27) the
following conditioning regimens were used: ﬂudarabine 150 mg/m2 with
IV busulfan 6.4 mg/kg in 16 patients (57%), ﬂudarabine 90 mg/m2 with
TBI 2 Gy in 6 patients (21%), ﬂudarabine 125 mg/m2 with melphalan
140 mg/m2 in 4 patients (14%). One patient underwent TLI of
12 Gy (120 cGy/day) on day − 11 to day − 7, then on day –4 to day
− 1 associated with ATG 1.5 mg/kg on day − 11 to day − 7. Twenty-two
patients in the MMUD group (81%) were administered rabbit
anti-thymocyte globulin (ATG) at 5 to 10 mg/kg over 1 to 3 days according
to local practice. GvHD prophylaxis consisted of CsA or tacrolimus, on day
− 3 or day − 1 in all patients according to local practice with either
mycophenolate mofetil (N=25, 89%) or methotrexate 15 mg/m2 at day +1,
10 mg/m2 at day+3 and day +6 (N=3, 11%).
In the CB group, 36 patients (97%) were conditioned with a
RIC consisting of ﬂudarabine (120–200 mg/m2), Cy 50 mg/kg and
TBI (2-4 Gy). One patient (3%) received ﬂudarabine 200 mg/m2,
Cy (2500 mg total dose) and melphalan 120 mg/m2. GvHD prophylaxis
consisted of CsA and mycophenolate mofetil started on day -3 for all
CB patients. After their publication in 2014, haploidentical transplantation
procedures were carried out according to the SFGM-TC guidelines.19,20
RESULTS
Patient and transplant characteristics
A total of 98 patients was included. Donor type was HAPLO, CB
and MMUD for 34 (35%), 27 (28%) and 37 patients (37%),
respectively. Statistically signiﬁcant differences between the
three groups were observed regarding prior exposure
to Brentuximab, prior auto-SCT, conditioning regimens,
ATG administration, TBI, stem cell source as well as day-100
chimerism (Table 1). Median age at allo-SCT was 28 years
(range: 16–68 years). The median number of treatments before
allo-SCT was 4 (range: 3 to 6). Median time between diagnosis and
transplant was 33 months (range: 9–176). Median follow-up
was 31 months for our whole cohort (range: 3–79). Median follow-
up was 21 (range: 9–52), 32 (range: 7–69) and 36 months
(range: 3–79) in the HAPLO, MMUD and CB groups, respectively.
Chimerism at day +100 was full donor in 72 patients (73%), mixed
in 15 patients (15%), full recipient in 3 patients (3%), whereas no
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data were available for 8 patients (8%). Details regarding patient
and transplant characteristics according to donor type are
available in Table 1 and 2, respectively.
Outcome analysis
A total of 29 patients (29%) relapsed after allo-SCT and 22 patients
(22%) died. Among the latter, 10 passed away because of
disease relapse or progression. Twelve patients (12%) died due to
NRM. Adverse events leading to NRM were as follows: acute GvHD
(N=2), idiopathic pneumonia syndrome (N=1), fungal infection
(N=2), sinusoidal obstruction syndrome (N=1), haemorrhage (N=1).
No speciﬁc cause of toxic death was reported for ﬁve patients.
Kaplan–Meier curves for OS and EFS are displayed for the whole
cohort and according to donor type in Figures 1 and 2, respectively.
GvHD analysis
Overall, 43 patients (43%) presented with acute GvHD (aGvHD).
Grade 2–4 aGvHD and grade 3–4 aGvHD were reported in
32 (32%) and 10 (10%) patients, respectively. The day-100 CI of
grade 2–4 aGvHD was 34% in the whole cohort, 28%, 27% and
45% in the HAPLO, MMUD and CB groups, respectively (P= 0.16).
The day-100 CI of grade 3–4 aGvHD was 11% in the whole cohort,
3, 9 and 21% in the HAPLO, MMUD and CB groups, respectively
(P= 0.06, Figure 3a).
Chronic GvHD (cGvHD) was diagnosed in 31 patients (32%)
while extensive cGvHD was reported in 9 patients (9%). The CI of
cGvHD at 2 years was 33% for the whole cohort; 15, 48 and 39% in
the HAPLO, MMUD and CB groups, respectively (P= 0.006). The
2-year CI of extensive cGvHD was 9, 19 and 3% in the HAPLO,
MMUD and CB groups, respectively (P= 0.07, Figure 3b).
Univariate analysis on outcome
Disease status at allo-SCT signiﬁcantly impacted OS (Po0.001),
CIR (P= 0.02), EFS (Po0.001) and GRFS (P= 0.002). As shown in
Figure 4, we observed a signiﬁcantly higher probability of GRFS in
patients who received a HAPLO allo-SCT (52% versus 22% and
31% in the CB and MMUD groups at 3 years, respectively, P= 0.02).
Higher GRFS was also observed in patients receiving
a NMA conditioning compared with a RIC (50% versus 27% at
3 years, P= 0.009). We noted no difference in OS (83% versus
83% at 3 years, P= 0.66), CIR (24% versus 28% at 3 years, P= 0.98),
NRM (12% versus 6% at 3 years, P= 0.43), EFS (64% versus 65% at
3 years, P= 0.55) and GRFS (42% versus 35% at 3 years, P= 0.93)
between patients in CR and PR at transplant for the whole cohort.
In the HAPLO group, we observed no difference in OS (78% versus
91% at 3 years, P= 0.32), EFS (80% versus 75% at 3 years, P= 0.93)
and GRFS (67% versus 60% at 3 years, P= 0.83) between patients
in CR (N= 15) and PR (N= 9) at transplant. In this subgroup, we
observed a trend towards lower CIR (7% versus 25% at 3 years,
Table 1. Patient characteristics
Patients characteristics N= 98 HAPLO MMUD CB P-valuea
N= 34 (35%) N= 27 (28%) N= 37 (37%)
Age at diagnosis (years)
o 25 52 (53%) 19 (56%) 13 (48%) 20 (54%) 0.82
⩾ 25 46 (47%) 15 (44%) 14 (52%) 17 (46%)
Age at transplant (years)
o 28 46 (47%) 15 (44%) 12 (44%) 19 (52%) 0.79
⩾ 28 52 (53%) 19 (56%) 15 (56%) 18 (48%)
Sex
Female 39 (40%) 16 (47%) 11 (41%) 12 (32%) 0.45
Male 59 (60%) 18 (53%) 16 (59%) 25 (68%)
Prior exposure to bendamustine
No 93 (95%) 30 (88%) 26 (96%) 37 (100%) 0.07
Yes 5 (5%) 4 (12%) 1 (4%) 0
Prior exposure to brentuximab
No 77 (79%) 20 (59%) 22 (82%) 35 (95%) 0.001
Yes 21 (21%) 14 (41%) 5 (18%) 2 (21%)
Treatment lines prior to allo-SCT
⩽ 4 77 (79%) 24 (71%) 20 (74%) 33 (89%) 0.13
4 4 21 (21%) 10 (29%) 7 (26%) 4 (11%)
Disease status per Cheson 1999 criteria
CR 51 (52%) 15 (44%) 12 (45%) 24 (65%) 0.36
PR 31 (32%) 13 (38%) 9 (33%) 9 (24%)
SD/PD 11 (11%) 6 (18%) 2 (7%) 3 (8%)
Missing data 5 (5%) 0 4 (15%) 1 (3%)
PET status
PET-negative 44 (45%) 14 (41%) 9 (33%) 21 (57%) 0.2
PET-positive 42 (43%) 19 (56%) 11 (41%) 12 (32%)
Missing data 12 (12%) 1 (3%) 7 (26%) 4 (11%)
Abbreviations: allo-SCT= allogeneic stem cell transplantation; CB= cord blood; HAPLO=haploidentical donor; MMUD=mismatch unrelated donor;
PET=positron emission tomography. aχ2-test or Fisher’s exact test when appropriate.
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P= 0.25) and higher NRM (13% versus 0% at 3 years, P= 0.18)
associated with CR, but this did not reach statistical signiﬁcance. In
the MMUD group, we observed no difference in OS (83% versus
89% at 3 years, P= 0.77), EFS (75% versus 62% at 3 years, P= 0.93),
NRM (17% versus 11% at 3 years, P= 0.77) between patients in
CR (N= 12) and PR (N= 9) at transplant. In this subgroup, we
observed a trend towards lower CIR (8% versus 27% at 3 years,
P= 0.47) and higher GRFS (42% versus 11% at 3 years, P= 0.52)
associated with CR, although this did not reach statistical
signiﬁcance. In the CB group, probabilities of EFS (50% versus
56% at 3 years, P= 0.58), GRFS (28% versus 22% at 3 years,
P= 0.54), CIR (42% versus 33% at 3 years, P= 0.55) and NRM
(8% versus 11%, P= 0.83) were similar between CR (N= 24) and
PR (N= 9) patients. In this subgroup, we observed a trend towards
higher OS (86% versus 66% at 3 years, P= 0.55) in CR patients, but
this did not reach statistical signiﬁcance. All results from univariate
analyses are displayed in Table 3.
Multivariate analysis on outcome
After adjustment for signiﬁcant covariates, MMUD and CB were
associated with signiﬁcantly lower GRFS (HR = 2.02, P= 0.03 and
HR= 2.43, P= 0.009, respectively, Cox model) compared with
HAPLO donors. Disease status at allo-SCT was the only
independent risk factor that correlated with lower OS (HR= 6.5,
Po0.001, Cox model) and lower EFS (HR = 3.42, P= 0.002,
Cox model). All multivariate analyses are displayed in Table 4.
DISCUSSION
To our knowledge, this is the ﬁrst study comparing patients who
received a RIC allo-SCT from all three types of alternative
HLA-mismatched donors, including CB, over the same time period
and including only HL patients. Standard end points such as
OS, EFS, CIR, NRM and EFS did not differ between the 3 groups.
However, lower CI of cGvHD and grade 3–4 aGvHD was observed
Table 2. Transplant characteristics
Transplant characteristics N=98 HAPLO MMUD CB P-valuea
N= 34 (35%) N= 27 (28%) N= 37 (37%)
Prior ASCT
No 8 (8%) 8 (23%) 0 0 0.001
Yes 89 (91%) 26 (77%) 27 (100%) 36 (100%)
Missing data 1 (1%) 0 0 1
Time to allo-SCT
o33 months 49 (50%) 16 (47%) 12 (44%) 21 (57%) 0.57
⩾ 33 months 49 (50%) 18 (53%) 15 (56%) 16 (43%)
Conditioning regimen
NMA 38 (39%) 31 (91%) 7 (26%) 0 o0.001
RIC 60 (61%) 3 (9%) 20 (74%) 37 (100%)
ATG
No 75 (76%) 33 (97%) 5 (18%) 37 (100%) o0.001
Yes 23 (24%) 1 (3%) 22 (82%) 0
TBI
No 25 (24%) 3 (9%) 20 (74%) 1 (3%) o0.001
Yes 73 (76%) 31 (91%) 7 (26%) 36 (97%)
Stem cell source
BM 19 (34%) 17 (50%) 2 (3%) CB o0.001
PBSC 37 (66%) 17 (50%) 25 (97%)
CMV risk
No 30 (31%) 9 (26%) 9 (33%) 12 (32%) 0.81
Yes 68 (69%) 25 (74%) 18 (67%) 25 (68%)
Sex mismatch
No 81 (83%) 31 (91%) 21 (78%) 29 (78%) 0.27
Yes 17 (17%) 3 (9%) 6 (22%) 8 (12%)
ABO mismatch
No 48 (50%) 23 (68%) 10 (37%) 15 (43%) 0.03
Yes 48 (50%) 11 (32%) 17 (63%) 20 (57%)
Missing data 2 (2%) 0 0 2
Day-100 chimerism
Full donor 72 (73%) 21 (62%) 22 (81%) 29 (78%) 0.001
Mixed 15 (15%) 12 (35%) 0 3 (8%)
Full recipient 3 (3%) 0 2 (7%) 1 (3%)
Missing data 8 (8%) 1 (3%) 3 (11%) 4 (11%)
Abbreviations: allo-SCT= allogeneic stem cell transplantation; ASCT= autologous stem cell transplantation; ATG= anti-thymocyte globulin; BM=bone
marrow; CB= cord blood; HAPLO= haploidentical donor; MMUD=mismatch unrelated donor; NMA=non-myeloablative; RIC= reduced-intensity
conditioning. aχ2-test or Fisher’s exact test when appropriate.
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Figure 3. Cumulative incidence of (a) grade 3-4 aGVHD and (b) cGVHD according to donor type. allo-SCT, allogeneic stem cell transplantation;
CB, cord blood; HAPLO, haploidentical donor; MMUD, mismatch unrelated donor. Cumulative incidences were compared using Gray’s test. A
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Figure 2. Kaplan–Meier probability curves of overall and event-free-survival after allo-SCT according to donor type. allo-SCT, allogeneic stem
cell transplantation; CB, cord blood; HAPLO, haploidentical donor; MMUD, mismatch unrelated donor. The Log rank test was used to compare
survival probabilities. A full color version of this ﬁgure is available at the Bone Marrow Transplantation journal online.
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in the HAPLO resulting in signiﬁcantly higher GRFS at 3 years,
which was conﬁrmed in multivariate analysis. It has been
suggested by our group21 and others14 that this new endpoint
might be more clinically relevant to assess not only disease
control after allo-SCT, but also GvHD-related comorbidities.
Our study is also the ﬁrst to report GRFS after allo-SCT for
HL. Nonetheless, in a recent retrospective study including 79
patients with advanced non-Hodgkin lymphomas, Garciaz et al.11
Table 3. Univariate analysis
3-year OS P-valuea 3-year CIR P-valueb 3-year NRM P-valueb 3-year EFS P-valuea 3-year GRFS P-valuea
Whole cohort 76% 29% 12% 58% 36%
Donor type
HAPLO 75% 25% 9% 66% 52%
MMUD 73% 0.57 25% 0.52 18% 0.45 56% 0.59 22% 0.02
CB 80% 36% 11% 53% 31%
Disease status at transplant
CR/PR 83% o0.001 26% 0.02 10% 0.38 64% 0.001 38% 0.26
SD/PD 30% 54% 18% 27% 27%
PET status at transplant
PET-negative 80% 0.44 23% 0.36 14% 0.56 63% 0.69 32% 0.65
PET-positive 70% 35% 9% 55% 43%
Conditioning type
NMA 75% 0.93 24% 0.58 6% 0.17 70% 0.11 50% 0.009
RIC 76% 32% 15% 52% 27%
Age at diagnosis
o25 80% 0.31 27% 0.41 11% 0.88 61% 0.42 41% 0.29
⩾ 25 71% 31% 13% 55% 31%
Age at transplant
o28 75% 0.9 28% 0.61 15% 0.37 57% 0.81 37% 0.89
⩾ 28 76% 30% 10% 60% 35%
Prior exposure to bendamustine
No 76% 0.98 29% 0.88 13% 0.39 57% 0.48 37% 0.39
Yes 75% 20% 0% 80% 0%
Prior exposure to brentuximab
No 72% 0.16 32% 0.29 13% 0.67 55% 0.21 32% 0.09
Yes 90% 21% 9% 69% 51%
Treatment lines prior to alloSCT
o4 72% 0.16 30% 0.85 14% 0.26 56% 0.36 35% 0.67
⩾ 4 89% 26% 5% 70% 39%
Prior auto-SCT
No 100% 27% 0.86 0% 0.27 73% 0.36 45% 0.36
Yes 73% 0.17 30% 13% 57% 35%
Time to allo-SCT
o33 months 79% 0.24 35% 0.31 10% 0.49 54% 0.67 35% 0.97
⩾ 33 months 72% 23% 14% 62% 37%
ABO mismatch
No 72% 0.61 32% 0.74 12% 0.77 55% 0.66 39% 0.32
Yes 80% 26% 10% 63% 34%
Sex mismatch
No 75% 0.58 30% 0.65 13% 0.45 56% 0.32 35% 0.84
Yes 79% 24% 6% 70% 41%
CMV risk
No 89% 0.09 29% 0.88 7% 0.34 64% 0.33 35% 0.94
Yes 70% 29% 14% 55% 36%
Abbreviations: allo-SCT= allogeneic stem cell transplantation; ASCT= autologous stem cell transplantation; ATG= anti-thymocyte globulin; BM=bone
marrow; CB= cord blood; CIR= cumulative incidence of relapse; EFS= event-free survival; GRFS=GvHD-free relapse-free survival; HAPLO=haploidentical
donor; MMUD=mismatch unrelated donor; NMA=non-myeloablative; NRM= non-relapse mortality; OS=overall survival; RIC= reduced-intensity
conditioning. aLog rank test. bGray’s test.
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observed a signiﬁcantly higher probability of survival without
relapse or severe cGvHD after an allo-SCT from HAPLO donors
compared to matched unrelated donors. Keeping in mind
the retrospective nature of those studies, both our ﬁndings
seem to indicate better GRFS after HAPLO allo-SCT for HL. In
other terms, our results suggest that despite lower cGvHD rates,
the GvL effect might be preserved after a T-cell replete, NMA/RIC
HAPLO allo-SCT. Kanate et al.22 as well as Ghosh et al.23 recently
reported similar ﬁndings in two large cohorts of lymphoma
patients receiving T-cell replete RIC HAPLO allo-SCT with PT
CY. The mechanisms underlying this segregation between the
GVH and GVL effect in that particular setting remain poorly
understood. Of note, several murine experiments have shown an
important role of regulatory T cells in modulating GVH/GVL
effects.24–27
Several authors have already shown encouraging results after
T-cell replete haploidentical allo-SCT for HL patients, although
limited comparative data are available. Data from the
Fred Hutchinson Cancer Research Centre (FHCRC) and John
Hopkins University8 showed comparable OS between
HLA-matched unrelated and HAPLO recipients, along with lower
NRM (9% at two years) and higher PFS (51%) in the HAPLO group.
Importantly, patients from the FHCRC received only one day
of PT CY at 50 mg/kg. The Italian group investigated in several
retrospective studies T-cell replete non-myeloablative haploiden-
tical allo-SCT with post-transplant cyclophosphamide using the
Baltimore approach18 for advanced HL patients. Using this
approach, Raiola et al.10 reported a cumulative incidence of
NRM and relapse of 4% and 31%, respectively. In another
retrospective study including 49 patients with refractory lym-
phoma, Castagna et al.28 observed 2-year PFS and OS probabilities
of 74% and 85%, respectively. Comparable outcomes were
observed in the present study (Table 3).
Not only do we report here better outcome for patients
receiving a HAPLO allo-SCT, but also the outcome was better in all
subgroups compared with previously published studies. Indeed,
lower OS and higher relapse rates have been reported after CB2,3,5
HAPLO8,10 and unrelated (matched or mismatched) donor
allo-SCT6,9 for relapsed/refractory HL. Although the deﬁnition of
chemorefractoriness varies among studies, it has been reported by
many to be the main adverse prognostic factor regardless of the
type of donor.1,3,5 We observed similar ﬁndings in our study, as
disease status, deﬁned as CR/PR versus SD/PD, was the only
independent risk factor impacting OS, CIR and EFS. The overall
better outcome reported here was likely due to a much higher
proportion (N= 51, 52% of the whole cohort) of patients in CR in
our cohort compared to other studies (14–41%).6,8,10,29 Further-
more, 23% of the HAPLO patients had not undergone an ASCT,
indicating a less heavily treated population. This may also account
for the better outcome observed in the HAPLO group.
In conclusion, in the absence of an HLA-identical donor a T-cell
replete, NMAC HAPLO allo-SCT with PT CY seems associated
with better outcome compared with other alternative donors
for patients with high-risk HL. Further studies should aim
at comparing HAPLO to HLA-compatible sibling and unrelated
donors in larger cohorts, ideally within prospective trials.
CONFLICT OF INTEREST
The authors declare no conﬂict on interest.
ACKNOWLEDGEMENTS
We thank all participating centers as well as our data manager Nicole Raus and
Rachel Tipton, the SFGM-TC secretary. JG sends special thanks to Leila Moukthari for
her most precious help updating our database and retrieving missing data.
Table 4. Multivariate analysis
OS EFS GRFS
HR CI P-valuea HR CI P-valuea HR CI P-valuea
Donor type
HAPLO 1 1.06–3.84 0.03
MMUD 2.02
CB 2.43 1.24–4.75 0.009
Disease status at allo-SCT
CR/PR 1 1
SD/PD 6.5 2.54–16.70 o0.001 3.42 1.55–7.55 0.002
Abbreviations: allo-SCT= allogeneic stem cell transplantation; CB= cord blood; CI= conﬁdence interval; CR= complete response; EFS= event-free survival;
GRFS=GvHD-free relapse-free survival; HAPLO= haploidentical donor; HR=hazard ratio; MMUD=mismatch unrelated donor; OS= overall survival;
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Figure 4. GvHD-free relapse-free survival (GRFS) according to donor
type. allo-SCT, allogeneic stem cell transplantation; CB, cord blood;
HAPLO, haploidentical donor; MMUD, mismatch unrelated donor.
The Log rank test was used to compare survival probabilities. A full
color version of this ﬁgure is available at the Bone Marrow
Transplantation journal online.
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